Schering AG Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Berlin Germany (1851)
Status: Acquired by Bayer (2009)

Organization Overview

First Clinical Trial
1996
NCT00925873
First Marketed Drug
1990
iloprost (ventavis)
First NDA Approval
1991
sargramostim (leukine)
Last Known Activity
2005

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Berlex | Berlex Laboratories, Inc. | BERLEX LABS | Schering SA

Active Ingredients

Marketed Drugs (4)

estradiol (progynon depot) (2005)

iloprost (ventavis) (1990)

norgestrel (Ovral) (2005)

sargramostim (leukine) (1991 NDA)

Drugs in Phase 3 Trials (3)

cytarabine (cytosar-u) (1 trial)

fludarabine (fludara) (1 trial)

idarubicin (idamycin) (1 trial)

Drugs in Phase 2 Trials (2)

Key: Schering AG (1) Acquired (1)

alemtuzumab (campath) (1 trial)

asoprisnil (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5